Document Detail

Intracerebral hemorrhage due to hemorrhagic disease of the newborn and failure to administer vitamin K at birth.
MedLine Citation:
PMID:  17195415     Owner:  NLM     Status:  MEDLINE    
In infants, intracerebral hemorrhage (ICH) is most likely the result of trauma or disturbances of coagulation function. Routine and standard care of the newborn includes the administration of vitamin K to prevent hemorrhagic disease of the newborn. We present two infants, the products of home deliveries, who did not receive vitamin K at birth. Both infants developed ICH at 5 weeks of age and presented with signs and symptoms of increased IC pressure. In both cases, recombinant factor VIIa was administered to correct coagulation function and allow immediate surgical intervention which included craniotomy and hematoma evacuation in one patient and placement of a ventriculostomy in the other to treat increased IC pressure. Despite this therapy, both infants were left with severe neurologic sequelae. These two cases illustrate that hemorrhagic disease of the newborn can occur when prophylactic vitamin K is not administered and that it can have devastating consequences. Given these issues, the routine administration of vitamin K to all infants is mandatory and should not be considered optional.
Dena Hubbard; Joseph D Tobias
Related Documents :
17447115 - Levels of bone collagen markers in preterm infants: relation to antenatal glucocorticoi...
20091505 - Vitamin k prior to preterm birth for preventing neonatal periventricular haemorrhage.
2278025 - Maternal vitamin a supplementation in relation to selected birth defects.
9722245 - Vitamin d status of breastfed pakistani infants.
21481745 - Low-voltage aeeg as predictor of intracranial hemorrhage in preterm infants.
22902075 - Neonatal respiratory morbidity in the early term delivery.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Southern medical journal     Volume:  99     ISSN:  0038-4348     ISO Abbreviation:  South. Med. J.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2007-01-01     Completed Date:  2007-01-23     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0404522     Medline TA:  South Med J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1216-20     Citation Subset:  AIM; IM    
Department of Pediatrics, University of Missouri, 3W-27G HSC, One Hospital Drive, Columbia, MO 65212, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antifibrinolytic Agents / therapeutic use*
Cerebral Hemorrhage / etiology*,  prevention & control,  radiography,  surgery
Factor VII / therapeutic use
Factor VIIa
Fatal Outcome
Infant, Newborn
Recombinant Proteins / therapeutic use
Tomography, X-Ray Computed
Vitamin K / therapeutic use*
Vitamin K Deficiency Bleeding / complications*,  prevention & control
Reg. No./Substance:
0/Antifibrinolytic Agents; 0/Recombinant Proteins; 0/recombinant FVIIa; 12001-79-5/Vitamin K; 9001-25-6/Factor VII; EC VIIa
Comment In:
South Med J. 2006 Nov;99(11):1199   [PMID:  17195407 ]
South Med J. 2007 Jun;100(6):612-3   [PMID:  17593579 ]
Summary for patients in:
South Med J. 2006 Nov;99(11):1317   [PMID:  17201037 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid fact...
Next Document:  Rural-urban differences in factors associated with poor blood pressure control among outpatients.